195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669)... von Rinaldi, A, Kwee, I, Bertoni, F, Viganò, L, Hess, D, Coceani, N, Sessa, C, Rivera, V.M, Bedrosian, C.L, Catapano, C.V

Volltext

321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules von Berk, L, Miller, D, Clapham, D, Loewy, J, Mita, M, Britten, C, Poplin, E, Bedrosian, C.L, Clackson, T, Rivera, V.M

Volltext

Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients von Courter, S.G, Bedrosian, C.L

Volltext

Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients von Courter, S.G, Bedrosian, C.L

Volltext

390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis von Desai, A.A., Janisch, L., Berk, L., Knowles, H.L., Rivera, V.M., Kindler, H.L., Stadler, W.M., Bedrosian, C.L., Ratain, M.J.

Volltext

411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials von Rivera, V., Berk, L., Mita, M., Tolcher, A., Rowinsky, E., Desai, A.A., Ratain, M.J., Clackson, T., Bedrosian, C.L.

Volltext

A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck von Brizel, David M., Leopold, Kenneth A., Fisher, Samuel R., Panella, Timothy J., Fine, Robert L., Bedrosian, C.L., Kenan, Patrick D., Huang, Andrew, Womack, Teresa, Bjurstrom, Toni, Dodge, Richard, Prosnitz, Leonard R.

Volltext